SEC Comment Letter for NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — May 20, 2020

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: May 20, 2020 · CIK: 0001389545 · Accession: 0000000000-20-004513

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-238317

Date

May 20, 2020

Author

Justin M. Hall, Esq.

Form

UPLOAD

Company

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

United States securities and exchange commission logo May 20, 2020 Justin M. Hall, Esq. President, Chief Executive Officer and General Counsel NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608 Re:NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 15, 2020 File No. 333-238317 Dear Mr. Hall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Abby E. Brown, Esq.

Show Raw Text

United States securities and exchange commission logo
May 20, 2020
Justin M. Hall, Esq.
President, Chief Executive Officer and General Counsel
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, CA 94608
Re:NovaBay Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 15, 2020
File No. 333-238317
Dear Mr. Hall:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Abby E. Brown, Esq.

SecProbe.io